feed,title,long_url,short_url
Benzinga,Needham Remains Bullish On BTRS; Sees Sharp Upside,https://benzinga.com/news/22/06/27886858/needham-sees-52-upside-in-btrs-reiterates-a-buy,https://bit.ly/3AaX2Bn
Benzinga,This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B,https://benzinga.com/general/biotech/22/06/27887513/this-analyst-says-arbutus-easl-presentations-outline-path-for-a-functional-cure-for-chronic-hepat,https://bit.ly/3yq4siY
